{"certainAgreement":{"otherDetails":"Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.","piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"The study was planned to have 2 parts: a single agent dose escalation (Part 1) followed by a dose expansion (Part 2).\n\nDue to the early termination of the study, Part 2 study was never initiated and the overall study consisted of only Part 1. The data displayed are from the Part 1 study which is the only 1 period of the study. Besides, the pharmacokinetic (PK) endpoints of this study were not conducted. Therefore no results of PK parameters are displayed."},"pointOfContact":{"email":"ClinicalTrials.gov_Inquiries@pfizer.com","organization":"Pfizer Inc.","phone":"1-800-718-1021","title":"Pfizer ClinicalTrials.gov Call Center"}}